Bladder cancer.

Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network (NCCN)
J Natl Compr Canc Netw. 2013 11 (4): 446-75

PMID: 23584347 · DOI:10.6004/jnccn.2013.0059

Bladder cancer is the fourth most common cancer in the United States. Urothelial carcinoma that originates from the urinary bladder is the most common subtype. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide recommendations on the diagnosis and management of non-muscle-invasive and muscle-invasive urothelial carcinoma of the bladder. This version of the guidelines provides extensive reorganization and updates on the principles of chemotherapy management.

MeSH Terms (15)

Administration, Intravesical Algorithms Antineoplastic Combined Chemotherapy Protocols Carcinoma Cystectomy Female Humans Male Muscle Neoplasms Neoadjuvant Therapy Neoplasm Invasiveness Neoplasm Staging Organ Sparing Treatments Urinary Bladder Neoplasms Urothelium

Connections (1)

This publication is referenced by other Labnodes entities: